Navigation Links
Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Valturna will be approved for sale in any additional markets. Nor can there be any guarantee that Tekturna will be approved for any additional indications or labeling in any market. Neither can there be any guarantee that Valturna, Tekturna or Diovan will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovativ
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
4. Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017
5. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... the enterprise replication cluster, faster loading speeds, higher ... Elasticsearch. This release happens to coincide with a ... GraphDB™ was formerly known as OWLIM. ... enterprise resilient RDF triplestore will also benefit from ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... 2011 Vaccinex, Inc. announced today that it has ... 1 clinical trial to assess the safety, tolerability, pharmacokinetics ... patients with advanced solid tumors. (Logo: ... antibody that blocks the activity of semaphorin 4D (SEMA4D). ...
... 4, 2011 Zeus, Inc., a global leader in ... expanded its capabilities and is now able to process ... Class 7 manufacturing environment. This expansion allows for the ... environment, resulting in compliance with stricter regulatory standards. ...
... announces that a new market research report is ... Opportunities in Biosimilar and Biobetter Drugs Markets ... Executive SummaryThe biosimilar and biobetter drugs market has ... following a series of changes in regulatory framework ...
Cached Biology Technology:Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Calif. The largest genome-wide association study ever ... cat allergies, has identified 16 new genetic associations ... collaboration between 23andMe, the leading personal genetics company, ... Children (ALSPAC), examined data for more than 53,000 ...
... the Denver Police Crime Lab and the University of Colorado, have ... leukocyte (white blood cell) and a cancer cell fuse to form ... ONE , may answer the question of how cancer cells travel ... tissues of the body the deadly process of metastasis. ...
... and medical students each received a one-year, $40,000 ... psoriatic arthritis. The National Psoriasis Foundation Amgen Medical ... scientists studying and treating psoriatic diseases by encouraging ... and psoriatic arthritis as physician researchers. The ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 2National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 3
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. ... and CHAPSO. Has reduced electrostatic interactions that ... on DEAE-cellulose. Aggregation number: 8-16. Purity: ... 2 O. Aggregation number 8 - 16, ...
... White crystalline solid. HYGROSCOPIC. Water-soluble zwitterionic detergent ... 252005) but differing in the length of ... extraction of mycoplasma membrane antigens under mild ... TLC. Soluble in H 2 O. ...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: